Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-Mediated protein transduction

Molecular Pharmacology

Volumn 61, Issue 2, 2002, Pages 269-276

  Yang, Yan ^a   Ballatori, Nazzareno ^a   Smith, Harold C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B100; GENE PRODUCT; LOW DENSITY LIPOPROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE THERAPY; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; RISK FACTOR; RNA EDITING; SIGNAL TRANSDUCTION;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CELLS, CULTURED; CYTIDINE DEAMINASE; GENE PRODUCTS, TAT; HEPATOCYTES; LIPOPROTEINS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; RISK FACTORS; RNA EDITING; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 0036158007     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.2.269     Document Type: Article

References (43)

1. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents
2. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia
3. Identification of GRY-RBP as an apo B mRNA binding protein that interacts with both apobec-1 and with apobec-1 complementation factor (ACF) to modulate C to U editing
4. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon
5. HMG-CoA reductase inhibitors: A look back and a look ahead
6. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100
7. Familial hypercholesterolemia
8. Apolipoprotein B mRNA editing in 12 different mammalian species: Hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins
9. Extract-specific heterogeneity in high-order complexes containing apo B mRNA editing activity and RNA-binding proteins
10. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48
11. Gene transfer of cytidine deaminase APOBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B mRNA editing in rabbits
12. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme ameliorates hypercholesterolemia in LDL receptor-deficient rabbits
13. Purification and Molecular cloning of a novel essential component of the apo B mRNA editing enzyme complex
14. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA
15. Kipl induces cell migration
16. Complete phenotypic characterization of the apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1
17. Regulation of hepatic apoB RNA editing in the genetically obese Zucker rat
18. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine
19. Low expression of the apolipoprotein B mRNA editing transgene in mice reduces LDL but does not cause liver dysplasia or tumors
20. In vivo protein transduction: Delivery of a biologically active protein into the mouse
21. Protein transduction: Unrestricted delivery into all cells
22. Disproportionate relationship between APOBEC-1 expression and apoB mRNA editing activity
23. Neurofibromatosis type I mRNA undergoes base-modification RNA editing
24. In vitro apolipoprotein B mRNA editing: Identification of a 27S editing complex
25. Overexpression of APOBEC-1 results in mooring-sequence-dependent promiscuous RNA editing
26. Determinants involved in regulating the proportion of edited apolipoprotein B RNAs
27. Apolipoprotein B RNA Sequence 3′ of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing
28. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: Studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes
29. Molecular cloning of an apo B messenger RNA editing protein
30. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production
31. Ethanol increases apolipoprotein B mRNA editing in rat primary hepatocytes and McArdle cells
32. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein
33. Insulin increases expression of apobec-1, the catalytic subunit of the apoB B mRNA editing complex in rat hepatocytes
34. ApoB mRNA editing: Validation of a sensitive assay and developmental biology of RNA editing in the rat
35. Normal perinatal rise in serum cholesterol is inhibited by hepatic delivery of adenoviral vector expressing apolipoprotein B mRNA editing enzyme in rabbits
36. Apolipoprotein B mRNA editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals
37. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif
38. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA editing enzyme
39. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1
40. Intracellular trafficking determinants in APOBEC-1 the catalytic subunit for cytidine to uridine editing of Apoβ mRNA
41. Partial characterization of the auxiliary factors involved in apo B mRNA editing through APOBEC-1 affinity chromatography
42. Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apo B mRNA editing